Eton Pharmaceuticals, Inc. (ETON)
NASDAQ: ETON · Real-Time Price · USD
14.13
-0.03 (-0.21%)
At close: Aug 1, 2025, 4:00 PM
14.41
+0.28 (1.98%)
After-hours: Aug 1, 2025, 6:20 PM EDT

Company Description

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases.

Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.

The company is also developing various product candidates, which are in late-stage development, including ET-400 for treating adrenal insufficiency; ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis.

Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals logo
CountryUnited States
Founded2017
IPO DateNov 13, 2018
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
Employees31
CEOSean Brynjelsen

Contact Details

Address:
21925 W. Field Parkway, Suite 235
Deer Park, Illinois 60010-7278
United States
Phone847 787 7361
Websiteetonpharma.com

Stock Details

Ticker SymbolETON
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001710340
CUSIP Number29772L108
ISIN NumberUS29772L1089
Employer ID37-1858472
SIC Code2834

Key Executives

NamePosition
Sean E. BrynjelsenPresident, Chief Executive Officer and Director
James R. Gruber CPAChief Financial Officer, Treasurer and Secretary
David C. KrempaChief Business Officer
Ipek Erdogan-TrinkausChief Commercial Officer
Danka RadosavljevicExecutive Vice President of Operations
Scott GrossenbachSenior Vice President of Sales Operations

Latest SEC Filings

DateTypeTitle
Jul 17, 2025SCHEDULE 13GFiling
Jul 8, 20258-KCurrent Report
Jun 27, 20258-KCurrent Report
Jun 20, 20258-KCurrent Report
Jun 12, 2025144Filing
Jun 10, 20258-KCurrent Report
Jun 3, 2025144Filing
May 28, 20258-KCurrent Report
May 13, 202510-QQuarterly Report
May 13, 20258-KCurrent Report